Home Forums Melanoma Diagnosis: Stage IV Articles related to melanoma

  • This topic is empty.
Viewing 4 posts - 1 through 4 (of 4 total)
  • Author
    Posts
  • #21870
    Violeta
    Participant

    Just for our info:

    ”Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma”

    http://annonc.oxfordjournals.org/content/25/3/747

    ‘{…}While both compounds have comparable clinical efficacy, vemurafenib but not dabrafenib decreases patients peripheral lymphocyte counts and alters CD4+ T cell phenotype and function. Thus, selective BRAFi can significantly affect patients’ peripheral lymphocyte populations. Fully understanding these effects could be critical for successfully implementing combinatorial therapies of BRAFi with immunomodulatory agents.

    #63807
    Violeta
    Participant

    I was thinking that it will be useful to post here articles or interesting research on melanoma. Me for example, I am reading almost everything I have access to..:-) and I am interested in more.

    I am sure a lot of you are doing the same.

    Thus, if you agree and find as well articles on melanoma to share, maybe it is nice have them in one place..

    Violeta

    #63808
    Violeta
    Participant

    Recent published article: although not very easy to understand the article contain information about how tumor resistance became reversible (patients respond again) with a drug holiday regime of Braf inhibitors (zelboraf for example).

    ”Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma”

    http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13121.html

    In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a ‘drug holiday’ and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.

    If somebody has access to full article please let me know, I am curious to read it.

    #63809
    Violeta
    Participant

    Through a friend I discovered yesterday an interesting article about the effect of copper on melanoma tumors:

    http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13180.html#access

    ‘Cu chelators used in the treatment of Wilson disease decreased tumour growth of human or murine cells transformed by BRAFV600E or engineered to be resistant to BRAF inhibition. Taken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers containing the BRAFV600E mutation”

    Linked to this I noticed also a pilot study combining trientina (a cooper chelator) and vemurafenib.

    http://clinicaltrials.gov/ct2/show/NCT02068079

    I hope something good will come out from this study.

Viewing 4 posts - 1 through 4 (of 4 total)
  • The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.